A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 420 participants.

Also called NCT02773368

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 420 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02773368
  • EudraCT 2015-001596-48
Other papers using this trial's data
  • Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes Diabetes, obesity & metabolism, 2019-06 DOI, PubMed 30761720, PMC6593861 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Canada, Finland, Hungary, India, Russia, Slovakia, Slovenia, Spain, Switzerland (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02773368. Randomized; no masking; primary purpose treatment. Start 2016-05-23 (actual); primary completion 2017-09-26 (actual). Results posted on 2018-10-23.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus
Acronym
DUALTM IX
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
insulin degludec/liraglutide
Intervention (Drug)
insulin glargine
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct02773368
Content hash
b3e10507252363e978cf28efbae67c006986a98c1b8af00ad331ced7ded69fb1